Quantity of eligible individuals: CDEC reviewed the uncertainty in the amount of patients with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some people who are categorized as owning moderate or reasonable ailment might have a serious bleeding phenotype, https://hemgenix50483.idblogz.com/36254131/hemgenix-fundamentals-explained